Praluent: how long were the pivotal tox studies?

“The primary nonclinical toxicity studies of alirocumab were conducted in rats and monkeys for up to 6 months duration with weekly subcutaneous and intravenous dosing.”

“The primary nonclinical toxicity studies of alirocumab were conducted in rats and monkeys for up to 6 months duration with weekly subcutaneous and intravenous dosing.”

“Route of administration Groups 2-4, subcutaneous: 5, 15, and 75 mg/kg/week Group 5, intravenous infusion (~30 min): 50 mg/kg/week only”